SG11201909062WA - Pharmaceutical formulation - Google Patents
Pharmaceutical formulationInfo
- Publication number
- SG11201909062WA SG11201909062WA SG11201909062WA SG11201909062WA SG 11201909062W A SG11201909062W A SG 11201909062WA SG 11201909062W A SG11201909062W A SG 11201909062WA SG 11201909062W A SG11201909062W A SG 11201909062WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- pharmaceutical formulation
- strasse
- english
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 235000015244 frankfurter Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17163830 | 2017-03-30 | ||
PCT/EP2018/057877 WO2018178134A1 (en) | 2017-03-30 | 2018-03-28 | Pharmaceutical formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909062WA true SG11201909062WA (en) | 2019-10-30 |
Family
ID=58461174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909062W SG11201909062WA (en) | 2017-03-30 | 2018-03-28 | Pharmaceutical formulation |
Country Status (22)
Country | Link |
---|---|
US (2) | US11559490B2 (fi) |
EP (2) | EP4286007A3 (fi) |
JP (1) | JP7228524B2 (fi) |
KR (1) | KR20190130017A (fi) |
CN (1) | CN110446707B (fi) |
AU (1) | AU2018246258B2 (fi) |
BR (1) | BR112019020269A2 (fi) |
CA (1) | CA3058286A1 (fi) |
DK (1) | DK3601277T3 (fi) |
ES (1) | ES2968399T3 (fi) |
FI (1) | FI3601277T3 (fi) |
HR (1) | HRP20231748T1 (fi) |
HU (1) | HUE064474T2 (fi) |
IL (2) | IL269668B2 (fi) |
LT (1) | LT3601277T (fi) |
MX (1) | MX2019011639A (fi) |
PT (1) | PT3601277T (fi) |
RS (1) | RS65052B1 (fi) |
SG (1) | SG11201909062WA (fi) |
SI (1) | SI3601277T1 (fi) |
TW (2) | TWI808077B (fi) |
WO (1) | WO2018178134A1 (fi) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
CN114072396B (zh) * | 2019-06-27 | 2024-02-02 | 南京明德新药研发有限公司 | 作为dna-pk抑制剂的喹啉和噌啉衍生物 |
WO2022058323A1 (en) | 2020-09-18 | 2022-03-24 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100134557A (ko) | 2008-01-11 | 2010-12-23 | 씨아이피엘에이 엘티디. | 고체 약제학적 투여 제형 |
EP2105130A1 (de) * | 2008-03-25 | 2009-09-30 | Ratiopharm GmbH | Pharmazeutische Formulierung und Verfahren zu deren Herstellung |
WO2012164578A1 (en) * | 2011-06-02 | 2012-12-06 | Hetero Research Foundation | Compositions and methods for preparing immediate release formulations of nilotinib |
KR102000312B1 (ko) * | 2011-10-14 | 2019-07-15 | 어레이 바이오파마 인크. | Erb2 (her2) 저해제의 고체 분산물 |
US20160000720A1 (en) | 2013-02-14 | 2016-01-07 | Aurobindo Pharma Limited | Pharmaceutical compositions comprising Tadalafil |
DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
KR102448369B1 (ko) | 2014-02-05 | 2022-09-28 | 머크 샤프 앤드 돔 엘엘씨 | Cgrp-활성 화합물에 대한 정제 제제 |
EP2913048A1 (en) * | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Pharmaceutical composition comprising trametinib |
JP6203702B2 (ja) | 2014-11-18 | 2017-09-27 | 信越化学工業株式会社 | ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法 |
-
2018
- 2018-03-28 DK DK18715593.2T patent/DK3601277T3/da active
- 2018-03-28 SI SI201831045T patent/SI3601277T1/sl unknown
- 2018-03-28 AU AU2018246258A patent/AU2018246258B2/en active Active
- 2018-03-28 KR KR1020197032000A patent/KR20190130017A/ko not_active Application Discontinuation
- 2018-03-28 EP EP23202392.9A patent/EP4286007A3/en active Pending
- 2018-03-28 FI FIEP18715593.2T patent/FI3601277T3/fi active
- 2018-03-28 JP JP2019553415A patent/JP7228524B2/ja active Active
- 2018-03-28 RS RS20240029A patent/RS65052B1/sr unknown
- 2018-03-28 PT PT187155932T patent/PT3601277T/pt unknown
- 2018-03-28 IL IL269668A patent/IL269668B2/en unknown
- 2018-03-28 SG SG11201909062W patent/SG11201909062WA/en unknown
- 2018-03-28 CA CA3058286A patent/CA3058286A1/en active Pending
- 2018-03-28 MX MX2019011639A patent/MX2019011639A/es unknown
- 2018-03-28 CN CN201880022126.5A patent/CN110446707B/zh active Active
- 2018-03-28 LT LTEPPCT/EP2018/057877T patent/LT3601277T/lt unknown
- 2018-03-28 WO PCT/EP2018/057877 patent/WO2018178134A1/en active Application Filing
- 2018-03-28 HU HUE18715593A patent/HUE064474T2/hu unknown
- 2018-03-28 US US16/498,943 patent/US11559490B2/en active Active
- 2018-03-28 HR HRP20231748TT patent/HRP20231748T1/hr unknown
- 2018-03-28 IL IL301979A patent/IL301979B2/en unknown
- 2018-03-28 ES ES18715593T patent/ES2968399T3/es active Active
- 2018-03-28 EP EP18715593.2A patent/EP3601277B1/en active Active
- 2018-03-28 BR BR112019020269A patent/BR112019020269A2/pt active Search and Examination
- 2018-03-30 TW TW107111175A patent/TWI808077B/zh active
- 2018-03-30 TW TW112122367A patent/TW202402297A/zh unknown
-
2022
- 2022-12-01 US US18/060,929 patent/US20230119567A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907034PA (en) | Methods of treating influenza | |
SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
SG11201810177VA (en) | Pet-imaging immunomodulators | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
SG11201908660RA (en) | N-substituted indole derivatives | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors |